Procter & Gamble Hygiene and Health Care Limited (PGHH.NS) Bundle
As investors scrutinize Procter & Gamble Hygiene and Health Care Limited's recent performance, the numbers tell a nuanced story: for the nine months ending March 31, 2025 the company reported sales of ₹3,374 crore versus ₹4,206 crore a year earlier, and revenue from operations in the March quarter stood at ₹991.63 crore (down 1.05% from ₹1,002.17 crore), yet the firm delivered a quarter PAT of ₹156.10 crore (a 1.1% rise), supported by a prior quarter sales uptick of 10% in Dec 2024 driven by portfolio strength; profitability pressures are visible with operating margin slipping to 21.14% from 25.68% and March quarter PBT of ₹193.53 crore, while earlier results showed resilience-Sep 30, 2025 PBT of ₹281.78 crore, OPM 24.79% and EPS of ₹64.65-balance-sheet conservatism is evident with total equity of ₹93,127 lakh and total assets of ₹213,341 lakh as of Sep 30, 2025, low debt levels, healthy current and quick ratios, net cash from operations of ₹51,840 lakh and net cash used in financing of ₹21,125 lakh in the same period; valuation headwinds include a 52-week low of ₹13,251.05 on March 11, 2025 and P/E pressure, while risks (tariffs, raw material volatility, regulatory shifts) and growth levers (feminine and health-care innovation, emerging-market expansion, digital and sustainability initiatives) make a close read of the full breakdown essential
Procter & Gamble Hygiene and Health Care Limited (PGHH.NS) - Revenue Analysis
Procter & Gamble Hygiene and Health Care Limited (PGHH.NS) reported a softer top line amid a challenging operating and macro-economic environment, while selectively offsetting the impact through portfolio strength and innovation across feminine care and health care.- Nine-month FY ending 31 Mar 2025 sales: ₹3,374 crore (down from ₹4,206 crore in prior-year nine-month period).
- Quarter ended 31 Mar 2025 - Revenue from operations: ₹991.63 crore, down 1.05% from ₹1,002.17 crore in Q4 Mar 2024.
- Quarter ended 31 Mar 2025 - Profit after tax (PAT): ₹156.10 crore, up 1.1% from approx. ₹154.36 crore in the year-ago quarter.
- Quarter ended 31 Dec 2024 - Sales grew ~10%, driven by a robust portfolio and new product introductions.
- Management attributes the overall revenue decline to a challenging macro environment, while continuing investments in innovations across feminine care and health care to meet evolving consumer needs.
| Period | Revenue (₹ crore) | Change vs Prior | PAT (₹ crore) | PAT Change vs Prior |
|---|---|---|---|---|
| Q4 ended 31 Mar 2025 | 991.63 | -1.05% vs Q4 Mar 2024 (1,002.17) | 156.10 | +1.1% vs Q4 Mar 2024 (≈154.36) |
| Nine months ended 31 Mar 2025 | 3,374.00 | -19.75% vs prior nine months (4,206.00) | - | - |
| Q3 ended 31 Dec 2024 | - (sales growth ~+10% reported) | +10% QoQ growth reported | - | - |
- Drivers mitigating revenue weakness: focused portfolio promotions, innovation launches in feminine care and health care, and price/mix management.
- Risks: sustained macro softness, consumer discretionary pressure, and competitive pricing in core categories.
- For further context on the company's strategic positioning, see Procter & Gamble Hygiene and Health Care Limited: History, Ownership, Mission, How It Works & Makes Money.
Procter & Gamble Hygiene and Health Care Limited (PGHH.NS) - Profitability Metrics
Key profitability indicators for the recent quarters show mixed signals: operating profit margin compression in the March 2025 quarter amid higher input costs, but recovery in absolute profits and strong per-share earnings by September 2025.
- Quarter ended Mar 31, 2025 - Operating profit margin fell to 21.14% from 25.68% in the same quarter a year earlier.
- Profit before tax (PBT) for Mar 2025 quarter: ₹193.53 crore (year‑on‑year decline).
- Profit after tax (PAT) for Mar 2025 quarter: ₹156.10 crore (1.1% increase YoY - prior year PAT ≈ ₹154.37 crore).
- Drivers of the OPM decline: increased raw material costs and other operational challenges.
- Quarter ended Sep 30, 2025 - PBT: ₹281.78 crore with an operating profit margin of 24.79% and earnings per share (EPS) of ₹64.65, indicating improved margin and stable profitability per share.
| Quarter | Operating Profit Margin | Profit Before Tax (₹ crore) | Profit After Tax (₹ crore) | Earnings Per Share (₹) |
|---|---|---|---|---|
| Mar 31, 2024 (YoY comparator) | 25.68% | - | ₹154.37 | - |
| Mar 31, 2025 | 21.14% | ₹193.53 | ₹156.10 | - |
| Sep 30, 2025 | 24.79% | ₹281.78 | - | ₹64.65 |
- Margin dynamics: sharp OPM decline in Mar 2025 reflects cost headwinds; partial margin recovery by Sep 2025 suggests operational leverage and/or pricing/portfolio effects.
- Profitability per share: EPS of ₹64.65 for Sep 2025 underscores shareholder-level stability despite quarter-to-quarter margin swings.
- Watch items for investors: raw material cost trends, scale benefits, and any sustained margin recovery across subsequent quarters.
Further context on the company's strategy, ownership and longer-term business model can be found here: Procter & Gamble Hygiene and Health Care Limited: History, Ownership, Mission, How It Works & Makes Money
Procter & Gamble Hygiene and Health Care Limited (PGHH.NS) - Debt vs. Equity Structure
Procter & Gamble Hygiene and Health Care Limited (PGHH.NS) exhibits a conservative capital structure as of September 30, 2025, with strong equity backing and no material uptick in reported debt levels.- Total equity: ₹93,127 lakh (as of Sep 30, 2025).
- Total assets: ₹213,341 lakh (as of Sep 30, 2025), reflecting sizeable asset coverage relative to equity.
- No significant increase in debt levels reported in recent financial statements; financing has prioritized operations and shareholder returns.
- Low debt-to-equity profile indicates lower financial risk and greater balance-sheet flexibility.
| Metric (as of Sep 30, 2025) | Amount (₹ lakh) | Notes |
|---|---|---|
| Total Assets | 213,341 | Asset base providing coverage for liabilities and investments |
| Total Equity | 93,127 | Strong equity base supporting operations and growth |
| Implied Total Liabilities (Assets - Equity) | 120,214 | Represents combined liabilities; company reports low reliance on external debt |
| Debt Profile | Not materially increased | Financing focused on operational needs and shareholder returns |
- Prudence in capital structure: the equity-to-assets ratio (~43.7%) underscores conservative financing (₹93,127 / ₹213,341 ≈ 0.437).
- Low reported leverage supports resilience to earnings volatility and interest-rate shocks.
- Capital allocation emphasis appears directed toward sustaining operations and returning capital to shareholders rather than leveraging growth through debt.
Procter & Gamble Hygiene and Health Care Limited (PGHH.NS) - Liquidity and Solvency
Procter & Gamble Hygiene and Health Care Limited (PGHH.NS) demonstrates solid short-term liquidity and prudent solvency management, underpinned by consistent cash generation and shareholder payouts. Key datapoints and trends are summarized below.- Current ratio: ~1.9 (healthy buffer to meet short-term liabilities).
- Quick ratio (ex-inventory): ~1.5 (indicates strong immediate liquidity).
- Operating cash flow: demonstrated variability with a notable decline in the quarter ending December 2024.
- Dividend policy: consistent dividend payouts maintained, reflecting confidence in solvency and cash-generation capacity.
- Net cash from operating activities (quarter ended 30 Sep 2025): ₹51,840 lakh.
- Net cash used in financing activities (quarter ended 30 Sep 2025): ₹21,125 lakh - indicating effective cash deployment and balance-sheet discipline.
| Metric | Value | Period / Note |
|---|---|---|
| Current Ratio | ~1.9 | Most recent reported (reflects comfortable short-term cover) |
| Quick Ratio | ~1.5 | Excludes inventory; shows strong liquid buffer |
| Operating Cash Flow (noted variability) | Decline observed | Quarter ending Dec 2024 showed a drop versus prior quarter |
| Net cash from operating activities | ₹51,840 lakh | Quarter ended 30 Sep 2025 |
| Net cash used in financing activities | ₹21,125 lakh | Quarter ended 30 Sep 2025 |
| Dividend Payout | Consistent | Ongoing regular dividends support investor confidence |
Procter & Gamble Hygiene and Health Care Limited (PGHH.NS) - Valuation Analysis
Procter & Gamble Hygiene and Health Care Limited (PGHH.NS) has seen material movements in its valuation profile over the past 12-18 months driven by operating performance, strategic actions and broader macro forces.- 52-week low: ₹13,251.05 (reached on March 11, 2025), reflecting a period of broad market weakness and company-specific headwinds.
- P/E dynamics: the price-to-earnings ratio has been under pressure as profitability metrics and margins have softened versus prior periods.
- Market capitalization: investor sentiment and cyclical market conditions have produced notable fluctuations in market cap.
- Peer comparison: analysts have flagged a decline in PGHH.NS's valuation multiple relative to industry peers.
- Strategic drivers: restructuring programs, product pricing actions and portfolio shifts have materially influenced investor expectations for future cash flow and valuation.
| Metric | Most Recent / Status | Implication |
|---|---|---|
| 52‑Week Low (date) | ₹13,251.05 (11‑Mar‑2025) | Indicative floor during market drawdown; reference for downside risk |
| P/E Ratio | Under pressure / declined from prior periods | Squeezed by lower earnings and margin contraction |
| Market Capitalization | Fluctuating with market sentiment | Reflects sensitivity to macro swings and company news |
| Valuation vs Peers | Noted decline by analysts | Relative multiple compression; prompts peer-based revaluation |
| External Factors | Global economic conditions, tariffs and trade dynamics | Can raise input costs and compress margins; affects forward multiples |
| Company Actions | Restructuring, pricing strategy changes | Short-term cost and revenue impacts; long-term valuation implications |
- Valuation sensitivity: earnings beats/misses, margin recovery or further restructuring updates are likely to move the multiple materially given current investor caution.
- Macro/tariff risk: changes in global tariffs or input-cost pass-through can shift expected free cash flow and hence the discount multiple investors apply.
- Relative positioning: unless operating trends converge with or exceed peers, the company may remain at a multiple discount in the near term.
Procter & Gamble Hygiene and Health Care Limited (PGHH.NS) - Risk Factors
Procter & Gamble Hygiene and Health Care Limited (PGHH.NS) operates in a dynamic consumer goods environment where multiple interlinked risks can materially affect performance, margins and investor returns. Below are the principal categories of risk, with quantified illustrations where relevant and practical mitigants.
- Global economic risks: slower GDP growth, rising tariffs and changing consumer preferences can reduce discretionary spend on premium hygiene and healthcare products. For example, a sustained 1% decline in urban consumption growth in India could shave ~1-2% off PGHH's revenue growth in a year, given historical urban contribution levels.
- Operational risks: fluctuations in raw-material prices (e.g., palm oil, petrochemical-derived raw materials for packaging, and specialty chemicals) and supply-chain disruptions can compress margins. A 10% rise in key input costs can cut gross margin by 150-300 basis points depending on product mix and pass-through.
- Regulatory and policy risks: changes in import duties, goods-and-services tax treatment, or product compliance regimes (health and safety standards) can increase product costs or delay launches. A tariff increase of 5 percentage points on imported components could raise unit costs by 1-3%, depending on import intensity.
- Competitive risks: intense competition from local brands and other multinational FMCG players can pressure prices and advertising spend. Market-share erosion of even 100-200 basis points in a major category (e.g., sanitaryware or baby care) can reduce segment EBITDA by mid-single-digit percentages.
- Financial risks: currency volatility (INR vs USD/EUR) affects imported inputs and royalty/licensing flows; interest-rate shifts impact financing costs. A 100-basis-point rise in interest rates increases annual interest expense on incremental borrowings proportionally-relevant if working capital needs spike during disruptions.
- Reputational risks: product quality or safety incidents can lead to recalls, litigation, regulatory fines and long-term brand damage. A significant recall in a leading SKU can reduce quarterly sales in the impacted category by double digits and elevate marketing spend to restore trust.
Examples of how these risks have measurable financial implications (illustrative quarterly/annual sensitivity):
| Risk Type | Trigger | Typical Impact | Potential P&L Effect |
|---|---|---|---|
| Raw material inflation | 10% spike in commodity prices | Higher COGS, lower gross margin | Gross margin down 150-300 bps; EBITDA down 3-6% |
| Currency depreciation (INR) | 5% INR depreciation vs USD | Costlier imports & licensing; FX loss on exposures | EBITDA down 1-2% unless hedged |
| Tariff / regulatory change | 5 percentage point tariff increase on imports | Increased unit costs or delayed launches | Net margin compression of 50-200 bps |
| Market-share loss | 200 bps share drop in key category | Lower volumes; higher trade/marketing spend | Revenue decline 1-3%; EBITDA fall 2-5% |
| Reputation / quality incident | Product recall affecting leading SKU | Immediate sales shock; remediation costs | Quarterly sales down 10-30% in category; one-off costs multiple crores |
Quantitative snapshot to contextualize the scale of risks (approximate recent-year figures):
| Metric | Recent Fiscal Year (approx.) | Notes |
|---|---|---|
| Revenue | ₹6,800 crore | Core domestic sales dominate; exports smaller share |
| Net Profit (PAT) | ₹1,050 crore | Margins sensitive to input cost and ad spend |
| Gross Margin | ~52% | Depends on SKU mix-premium products higher margin |
| Net Debt / (Cash) | Net cash ~₹1,200 crore | Low leverage historically; buffer against shocks |
| Return on Equity (ROE) | ~18-22% | Reflects strong brand and pricing power |
- Mitigants: diversified product portfolio, pricing power in premium segments, hedging policies for FX exposure, long-term supplier contracts, and contingency inventory strategies to reduce short-term supply disruptions.
- Monitoring: investors should track commodity price indices, INR movements, category volumes, regulatory notices, and quarterly margin trends as leading indicators of emerging risk materialization.
Further context on ownership, institutional flows and investor profile is available here: Exploring Procter & Gamble Hygiene and Health Care Limited Investor Profile: Who's Buying and Why?
Procter & Gamble Hygiene and Health Care Limited (PGHH.NS) - Growth Opportunities
Procter & Gamble Hygiene and Health Care Limited (PGHH.NS) sits at the intersection of durable brand equity and expanding consumer demand across personal care, feminine hygiene, and health-care adjuncts. Several measurable avenues can materially influence revenue and margins over the next 3-5 years.- Innovation in feminine care and health care portfolios: targeted R&D and product premiumization can drive ASP (average selling price) expansion and category penetration.
- Emerging-market expansion: higher volume growth potential in tier-2/3 Indian cities and select international markets.
- Strategic partnerships and M&A: inorganic moves to acquire adjacent brands, tech, or supply-chain capabilities to accelerate scale.
- Digital transformation: process automation, demand forecasting, and direct-to-consumer (D2C) capabilities to optimize working capital and OPEX.
- Sustainability-led product lines: biodegradable/fiber-reduced products and recyclable packaging targeting environmentally conscious cohorts.
- E‑commerce acceleration: omnichannel and marketplace strategies to capture rising online spend on health and hygiene categories.
| Opportunity | Relevant Metric / Estimate | Implication for PGHH.NS |
|---|---|---|
| Feminine care market (India) | Estimated market size INR 8,000-12,000 crore; projected CAGR ~10-15% (near-term) | Room for premiumization and penetration gains through tailored SKUs and lower-unit affordable packs. |
| Health-care adjuncts (OTC & consumables) | Addressable market estimated INR 6,000-9,000 crore; rising outpatient & preventive health spend | Cross-sell and bundling with existing distribution; higher gross margins on niche products. |
| E‑commerce penetration | Online share of personal care purchases ~15-25% (growing ~20-30% YoY in recent years) | Investments in D2C, marketplace optimization and digital marketing can lift sales at lower marginal cost. |
| Sustainability product premium | Willingness-to-pay premium 5-20% among targeted cohorts | Opportunity for margin expansion if cost of sustainable inputs is managed. |
| Operational efficiency (digital/automation) | Potential SG&A reduction 3-6 percentage points over 3 years via process automation | Improves EBIT margins and frees cash for brand/M&A investments. |
- R&D pipeline concentration: focus on absorbency technology, skin-sensitive formulations, and biodegradable packaging to capture both mass and premium segments.
- Geographic rollout model: prioritize high-density urban expansion followed by accelerated distribution in mid-tier towns using smaller pack sizes to drive trial.
- M&A/partnership playbook: target niche health brands (revenue INR 50-300 crore) and digital-native brands with rapid online traction to add growth engines quickly.
- Digital KPIs: increase D2C contribution to sales to 8-12% within 2-3 years; reduce digital CAC via subscription and CRM-driven retention.
- Sustainability metrics: aim for X% recycled content and Y% reduction in single-use plastic per unit (set measurable annual targets tied to product launches).
| Scenario | Revenue CAGR | EBIT Margin Impact | Notes |
|---|---|---|---|
| Base (organic growth) | 6-8% p.a. | Stable | Continued category growth, steady market share. |
| Accelerated (innovations + e‑commerce) | 10-14% p.a. | +200-400 bp | Higher ASPs, D2C mix, efficiency gains. |
| Acquisition-led | 12-18% p.a. | +300-600 bp (post-integration) | Successful tuck-ins and cross-sell; integration risk applies. |
- Launch 2-4 differentiated SKUs per fiscal year targeting premium & eco-conscious segments.
- Expand distributor reach by 20-30% in semi-urban/rural nodes and introduce trial packs (lower price points).
- Deploy AI-driven demand planning to cut stock-outs and reduce inventory days by 10-15%.
- Form 1-2 strategic partnerships or bolt-on acquisitions annually targeting digital brands or category adjacencies.
- Quarterly revenue split: offline vs online growth rates and ASP trends.
- Gross margin trajectory relative to input-cost inflation and premiumization mix.
- Marketing ROI: CAC payback period for D2C channels and new product launch economics.
- Integration milestones and revenue synergies for any announced M&A.
- Sustainability KPIs disclosed (recycled content, packaging weight reductions, scope 1-3 targets).
Procter & Gamble Hygiene and Health Care Limited (PGHH.NS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.